Effect of Secukinumab on Cardiorenal Outcomes in Patients With Cardiorenal Metabolic Syndrome and Atherosclerotic Cardiovascular Disease

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 100 participants.

Also called NCT07704190

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07704190
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07704190. Randomized; no masking; primary purpose treatment. Start 2026-07-15 (anticipated); primary completion 2028-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Secukinumab on Cardiorenal Outcomes in Patients With Cardiorenal Metabolic Syndrome and Atherosclerotic Cardiovascular Disease
Condition
Cardiorenal Metabolic Syndrome
Condition
Atherosclerotic Cardiovascular Disease
Condition
Hypertension
Condition
Type 2 Diabetes Mellitus
Condition
Peripheral Arterial Disease
Condition
Carotid Artery Stenosis
Intervention (Biological)
Secukinumab (75 mg)
Intervention (Other)
Standard Medical Therapy
Lead sponsor
Peking University Third Hospital (class: other)

Record details

Record id
cardio:ct-nct07704190
Content hash
bc400021cf3d1bfce11cfdf665a75348e27faad289850f447cb49cba17a0c324